The largest changes include additions that address harmful payer policies, telemedicine authorization and patient compensation funds.
UHC Formulary Change Impacts Coverage for Ustekinumab
Effective Sept. 1, the brand name drug Stelara will no longer be covered on the UnitedHealthcare commercial plan prescription drug list.
At Summer Meeting, Insurance Legislators Discuss Policies Impacting Rheumatology
The National Council of Insurance Legislators (NCOIL) 2025 Summer Meeting, held July 16–19 in Chicago, Ill., included discussion of several policy issues relevant to rheumatology.
What ASTP/ONC’s 2025 Regulations Mean for Rheumatologists
The ASTP/ONC’s recently updated United States Core Data for Interoperability Version 6 includes new data elements and applicable standards to support the provision of precision medicine and better patient care across the healthcare system.
Medicare Drug Price Negotiation: What ACR Members Need to Know Ahead of Round Three
As the program enters its third round of negotiations, ACR members should be aware of several upcoming changes relevant to rheumatology.
White Bagging: A ‘Prescription for Disruption’ in Rheumatologic Care
In a recent op-ed published by MedCity News, rheumatologist and ACR Insurance Subcommittee Chair Michael Feely, MD, delivers a powerful critique of the insurance practice known as white bagging, calling it a “prescription for disruption” that threatens the quality and timeliness of patient care.
Advancing Equity and Access to Care with the Association of Women in Rheumatology
At the recent Association of Women in Rheumatology annual conference, AWIR and ACR leaders discussed advocacy’s important role in supporting equitable rheumatologic care.
Lowest Price, Highest Risk? New Drug Policy’s Potential Effect on Rheumatology
On July 31, President Trump sent formal letters to the CEOs of 17 major pharmaceutical companies, laying out several requirements the companies must meet within 60 days or face unspecified consequences. These include Most-Favored-Nation pricing for Medicare, Medicaid and private markets.
Rheumatology Could Face New Challenges Under Drug Tariff Reforms
A 15% tariff on all European Union exports, including pharmaceuticals, went into effect on Aug. 7. The tariff could impact the cost of providing care, patient access to therapies and drug research and development.
DOJ Tightens Oversight of DEI Programs: Implications for Rheumatology
A July 30 memo from Attorney General Pam Bondi clarifies how federal anti-discrimination laws apply to programs that might involve discriminatory practices, including those that fall under the umbrella of diversity, equity and inclusion.
- 1
- 2
- 3
- …
- 826
- Next Page »